HOME >> BIOLOGY >> NEWS
Genome-wide mouse study yields link to human leukemia

s.

While it was Caligiuri's laboratory that designed the mouse model, it was Plass who supervised the methylation studies. He and his colleagues used a system called Restriction Landmark Genome Sequencing (RLGS) to compare methylation patterns among the three groups of mice a method of using enzymes and gel electrophoresis to map tiny bits of DNA on a grid. The stretches of DNA, referred to as fragments, show up as smudgy blobs on a test film. If a fragment is dark and definite, it is not methylated. If, on the other hand, it loses at least 30 percent of its intensity, it is regarded as methylated.

In the study, the research team tested 2447 fragments in each animal. They found anywhere from 45 to 209 (.8 percent to 8.5 percent) of the fragments methylated in the mice with cancer, but only one or two methylated fragments in the other mice.

"Interestingly, that same range of methylated fragments is exactly what we find in human leukemia, too," says Caligiuri, "so that gives added merit to our mouse model as an investigative tool."

Using data from the methylation studies, Caligiuri and Plass were able to identify a particular stretch of DNA, called Id4, as a tumor suppressor gene.

Tumor suppressor genes help control cancer by identifying and getting rid of defective cells before they have a chance to mature and divide. When tumor suppressor genes lose that ability as they can if they are silenced through methylation or some other process, it gives cancer a chance to establish a foothold and spread.

Caligiuri says much more work needs to be done, but adds that the identification of Id4 as a likely tumor suppressor gene gives clinicians another possible target for intervention.

"We already have a drug, decitabine, that we know can reverse the effects of methylation," says Plass. "We are just beginning to figure out how it best works in humans, but simply knowing that we have a new target that may be meanin
'"/>

Contact: Michelle Gailiun
Gailiun.1@osu.edu
614-293-3737
Ohio State University
20-Feb-2005


Page: 1 2 3

Related biology news :

1. Genome-wide search unearths surprising clues for diabetes and triglycerides
2. OHSU turns mouse into factory for human liver cells
3. Virtual mouse brains now available online
4. New approaches to endometriosis treatment -- mouse experiments point the way
5. New mouse model closely mimics human cancers
6. Statin treatment improves spatial memory in mouse models of Alzheimers
7. Treatment extends survival in mouse model of spinal muscular atrophy
8. UCSF stem cell study reveals cells capability in mouse brain tissue repair
9. Mutant mouse provides insights into breast cancer
10. Mapping the mouse genome
11. MRSA vaccine shows promise in mouse study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Genome wide mouse study yields link human leukemia

(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)...   NexID Biometrics LLC, whose spoof-mitigation technology ... announced the beginning of shipments of version 2.0 of ... company, based in Potsdam, N.Y. , ... which began here today at the Walter E. Washington ... its SDK boosts the accuracy rate range to 96.5 ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
(Date:4/23/2015)... Proove Biosciences , a commercial ... to announce the launch of Proove Non-Opioid ... 62 genetic variations to predict good versus poor ... non-opioid pain medications, namely ibuprofen (brand name Advil, ... Xanax) and acetaminophen (brand name Tylenol). , ...
(Date:4/23/2015)... Texas (PRWEB) April 23, 2015 ReliantHeart's ... True Flow (blood flow through the device) in real ... by Numerex, the world’s leading provider of Machine to ... , True Flow via VADLink.com can ... there is any drop in flow below a minimum ...
(Date:4/22/2015)... , April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today ... first quarter 2015 on Thursday, May 7, 2015 after ... a webcast and conference call for 4.30 pm ET ... Live audio of the conference call will be ... investors, members of the news media and the general ...
(Date:4/22/2015)... 2015 2015 HIMSS Annual Conference & ... of the 9th annual Venture+ Forum pitch competition for ... selected to deliver live pitch presentations to a panel ... HIMSS15 held last week in Chicago ... professionals and 1,200 exhibiting companies from around the world, ...
Breaking Biology Technology:Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2TowerView Health Named Venture+ Forum Pitch Competition Winner At HIMSS15 2TowerView Health Named Venture+ Forum Pitch Competition Winner At HIMSS15 3
Cached News: